Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Advanced Solid Malignancy, × capivasertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 3 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Healthy Participants 2 Endometrial Neoplasms 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumour 1 Neoplasm Metastasis 1 Moderate Hepatic Impairment 1 Melanoma 1 Hereditary Sensory and Autonomic Neuropathies 1 Hematologic Neoplasms 1 Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) 1 Chondrosarcoma 1 Advanced Solid Tumours 1 Advanced Solid Malignancy, 1 Advanced Solid Malignancy 1 Advanced Cancer 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01895946 2016-05-25

OAK

AstraZeneca

Phase 1 Completed

33 enrolled 14 charts

Advanced Solid Malignancy,

Data powered by HemOnc (CC BY 4.0) Colophon ⚡